The transduction cascade of the androgenic receptor (AR) plays a significant role in the development and advancement of prostate cancer [8].Luteinizing hormone-releasing hormone (LHRH): A luteinizing hormone-releasing hormone (LHRH) agonist is a type of medication that stimulates the release of luteinizing hormone. Here, AR is linked to prostate carcinoma.